IM0310

Geistlich Biomaterials The successful duo now also avail- able as Combi-Kit Collagen The new Geistlich Combi-Kit Collagen com- binestwoestablishedandreliableproductsin asinglepackage:GeistlichBio-Oss® Collagen 100 mg and the native collagen membrane GeistlichBio-Gide® inanewsizeof16x22mm. The Geistlich Combi-Kit Collagen® offers the perfect solution for Ridge Preservation, i.e. for the treatment of alveolar bone defects followingtoothextraction,aswellasforminor augmentations. Today the combined appli- cation of bone substitute materials and re- sorbable membranes to treat bone defects has already become clinical routine and shows predictable and effective results (Aghaloo 2007; Sammartino 2009). Scientificevidenceandawealthofpracticalexperiencereportedhavealsoshownthattheinsertionof Geistlich Bio-Oss® Collagen in an extraction socket may be the ideal way to preserve the alveolar di- mensions (Ackermann 2009),and the inevitable loss of the bundle bone – and therefore of the buccal bone lamellae—following tooth extraction is compensated (Araujo 2008;Araujo 2009). Geistlich Biomaterials Bahnhofstr. 40, 6110 Wolhusen, Switzerland E-mail: info@geistlich.ch, Website: www.geistlich.ch AD Straumann Medical Device Technology of the Year Award for Straumann’s Roxolid Straumann, a global leader in regenerative, restorativeandreplacementdentistry,hasbeen presented with the 2009‘Medical DeviceTech- nologyoftheYearAward’forRoxolid® ,thecom- pany’s innovative high performance material for dental implants. TheAward recognizes excellence in technological innovation and is one of the Best PracticesAwards bestowedbyFrost&Sullivan.EngineeredanddevelopedbyStraumann,Roxolidisanalloyoftitanium andzirconiumwhichhasbeendesignedtoincreasereliabilityandconfidencewithsmalldiameterim- plants. Roxolid can accommodate the sophisticated microstructuring processes required for Strau- mann’s SLActive® surface technology,which enhances osseointegration.Roxolid has been undergo- ingabroadprogramofclinicaltrialsinninecountries.Involving60centersandmorethan300patients, thisisoneofthelargestclinicalresearchprogramseverundertakenbyadentalimplantcompanyprior to market launch.Apart from the clinical program, Roxolid was made available to 450 selected spe- cialists in a controlled release program,in which more than 11,000 implants were distributed. Institut Straumann AG Peter Merian-Weg 12, 4052 Basel, Switzerland E-Mail: info@straumann.com, Website: www.straumann.com Susanne Breuer, Stephen Booth and Sandro De Gruttola represented Straumann at the Award Ceremony.